Nature Reviews Neurology

Papers
(The H4-Index of Nature Reviews Neurology is 59. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
Lymphatic propagation of α-synuclein439
Microglia, spreaders of Aβ seeds389
Transmembrane protein interacts with α-synuclein to confer risk of PD338
Promising results for antisense RNA therapy in mouse models of diffuse midline glioma261
Ventricular enlargement caused by aducanumab252
Getting specific: targeting Fc receptors in myasthenia gravis230
Brain stimulation aids walking after spinal injury229
Deciphering nociplastic pain: clinical features, risk factors and potential mechanisms225
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications211
Global synergistic actions to improve brain health for human development197
Diagnosis and management of migraine in ten steps184
Refining oxytocin therapy for autism: context is key179
Neural cell state shifts and fate loss in ageing and age-related diseases175
NODDI reveals brain microstructural changes in multiple sclerosis172
Disease-specific modifications of tau protein169
Continuous levodopa production by an artificial enzyme168
CD11c+ macrophages mediate brain-to-gut α-synuclein trafficking167
The impact of rare genetic variants on Alzheimer disease166
Spinal muscular atrophy treatment in utero151
The role of the gut microbiota in multiple sclerosis150
Mitochondrial DNA instability in Huntington disease149
Study reveals new ALS risk genes127
Microglia subset associated with high-grade glioma125
Rapidly progressive dementias — leukodystrophies as a potentially treatable cause121
Is post-stroke cognitive impairment all about real estate?118
The Digitized Memory Clinic114
TREM2 mediates phagocytosis in glioblastoma111
Maternal immune activation and neuroinflammation in human neurodevelopmental disorders111
Imperatives and co-benefits of research into climate change and neurological disease111
Amyloid-β: a potential link between epilepsy and cognitive decline105
Ultrasound lets gene therapy into the brain103
Brain volume is associated with cognition in MS101
Role for endogenous retrovirus in FTD100
Menopause influences tau pathology99
Neurological care for LGBT+ people98
Amyloid plaques: hotspots for microglial turnover98
Management of freezing of gait — mechanism-based practical recommendations97
Psychosis-causing lesions mapped to a hippocampal circuit94
α-Synuclein pathology as a target in neurodegenerative diseases93
Neuroinflammation predicts cognitive decline in FTD89
The challenges of anti-tau therapeutics in Alzheimer disease89
Blood GFAP as an emerging biomarker in brain and spinal cord disorders84
Racial differences in the response to multiple sclerosis therapy83
Gene therapy effective in model of infantile parkinsonism83
MRI-based deep learning for TLE diagnosis82
Diversity, equity and inclusion in neurology80
Brain imaging illuminates cognitive impairment in multiple sclerosis79
APOE ε4 influences Parkinson disease progression78
Precision neuroimmunology in multiple sclerosis — the horizon is near72
Author Correction: Viral pathogens increase risk of neurodegenerative disease72
First trials test targeting of α-synuclein for Parkinson disease67
Parkinson disease pathology can originate in the kidney65
Gene therapy for seizures in focal cortical dysplasia65
New IDEAS about amyloid, race and dementia disparities64
Evidence for altered astrocyte function in Duchenne muscular dystrophy64
The noradrenergic subtype of Parkinson disease: from animal models to clinical practice64
Author Correction: Why won’t it stop? The dynamics of benzodiazepine resistance in status epilepticus63
Food is brain medicine — relevance and translation to neurology62
Neurosteroids alleviate seizures in rats61
Glymphatic dysfunction in PD clinical progression59
0.029226064682007